Supplementary Figure S2 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Figure S2. Change from baseline in tumor size and tuvusertib dose levels (FAS/SAF Analysis Set)
Supplementary Figure S2 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors | Synapse